Long-acting GLP-1 receptor agonist for metabolic research.
Semaglutide is a long-acting GLP-1 receptor agonist widely studied for glycemic control and body-weight regulation in metabolic research.
Selective GLP-1R agonism enhances glucose-dependent insulin secretion, suppresses glucagon, and slows gastric emptying.
Peptide engages target receptor with high affinity.
Downstream intracellular pathways activate.
Gene expression and protein synthesis shift.
Measurable change in the studied biomarker.
Phase 3 RCT of weekly semaglutide 2.4 mg vs. placebo in adults without diabetes.
Mean weight loss −14.9% vs. −2.4% placebo with improved cardiometabolic markers.
Pre-approval CV outcomes trial across two semaglutide doses.
26% reduction in composite MACE vs. placebo.
Compared semaglutide 1.0 and 2.4 mg vs. placebo on weight in T2D.
Weight reductions of 9.6% (2.4 mg) vs. 3.4% placebo with HbA1c improvement.
Lyophilized -20°C. Reconstituted: 2–8°C, use within 28 days.
Strictly for in-vitro laboratory and research investigations.
Not approved for diagnostic, therapeutic, or veterinary application.
Handling restricted to licensed researchers and laboratory staff.
Warning — Semaglutide is supplied solely for legitimate laboratory research. Any administration to humans or animals is strictly prohibited and may violate federal, state, or local law. By purchasing, the researcher accepts full responsibility for safe handling, storage, and lawful use.
